University Of Glasgow

In patients with angina with nonobstructive CAD, invasive testing increased the likelihood of an angina endotype diagnosis and improved treatment satisfaction compared with controls, but did not improve angina burden, researchers reported.

The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with reduced initiation of new treatments for hyperuricemia and gout, according to a post hoc analysis of DAPA-HF and DELIVER.

PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.

Approximately 48% patients who develop symptomatic COVID-19 either fail to recover or achieve only partial recovery within 6 to 18 months after infection, according to data published in Nature Communications.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.

Living a healthier lifestyle can lower the risk for dementia for adults with type 2 diabetes, according to a speaker at the European Association for the Study of Diabetes annual meeting.

In adults with HF with preserved or mildly reduced ejection fraction, neprilysin inhibition with sacubitril/valsartan did not impair cognitive function compared with valsartan, according to a speaker.

Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

The SGLT2 inhibitor dapagliflozin safely reduced risk for worsening HF or CV death among adults with HF with reduced ejection fraction compared with placebo regardless of frailty status, researchers reported.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.